+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Biological Therapy Market Research Report by Product, Distribution Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 156 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5336921
UP TO OFF until Dec 31st 2022
The United States Cancer Biological Therapy Market size was estimated at USD 10.65 billion in 2021, USD 12.46 billion in 2022, and is projected to grow at a CAGR 13.38% to reach USD 22.63 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Cancer Biological Therapy to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Product, the market was studied across Cancer Growth Blockers, Monoclonal Antibodies, and Vaccines.
  • Based on Distribution Channel, the market was studied across Hospital and Retail & Mail Order Pharmacies.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Biological Therapy market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Biological Therapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Cancer Biological Therapy Market, including AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, EnGeneIC Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis International AG, Otsuka Pharmaceutical Co., Ltd, Pfizer, Inc, Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Cancer Biological Therapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Cancer Biological Therapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Cancer Biological Therapy Market?
4. What is the competitive strategic window for opportunities in the United States Cancer Biological Therapy Market?
5. What are the technology trends and regulatory frameworks in the United States Cancer Biological Therapy Market?
6. What is the market share of the leading vendors in the United States Cancer Biological Therapy Market?
7. What modes and strategic moves are considered suitable for entering the United States Cancer Biological Therapy Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Cancer Biological Therapy Market, by Product
6.1. Introduction
6.2. Cancer Growth Blockers
6.3. Monoclonal Antibodies
6.4. Vaccines
7. Cancer Biological Therapy Market, by Distribution Channel
7.1. Introduction
7.2. Hospital
7.3. Retail & Mail Order Pharmacies
8. California Cancer Biological Therapy Market9. Florida Cancer Biological Therapy Market10. Illinois Cancer Biological Therapy Market11. New York Cancer Biological Therapy Market12. Ohio Cancer Biological Therapy Market13. Pennsylvania Cancer Biological Therapy Market14. Texas Cancer Biological Therapy Market
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. AbbVie, Inc
16.2. Amgen Inc.
16.3. Astellas Pharma Inc.
16.4. AstraZeneca PLC
16.5. Bausch Health Companies Inc.
16.6. Bayer AG
16.7. Bristol-Myers Squibb
16.8. Celgene Corporation
16.9. Eisai Co., Ltd.
16.10. Eli Lilly and Company
16.11. EnGeneIC Ltd
16.12. F. Hoffmann-La Roche AG
16.13. GlaxoSmithKline PLC
16.14. Hikma Pharmaceuticals PLC
16.15. Incyte Corp
16.16. Johnson & Johnson Services, Inc,
16.17. Merck & Co., Inc.
16.18. Novartis International AG
16.19. Otsuka Pharmaceutical Co., Ltd
16.20. Pfizer, Inc
16.21. Sanofi SA
16.22. Spectrum Pharmaceuticals, Inc.
16.23. Takeda Pharmaceutical Company Limited
16.24. Teva Pharmaceutical Industries Ltd
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
FIGURE 8. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2027
FIGURE 11. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, 2019-2027 (USD BILLION)
FIGURE 12. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 13. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2019-2027 (USD BILLION)
FIGURE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, 2019-2027 (USD BILLION)
FIGURE 16. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 17. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 18. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD BILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 20. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL, 2019-2027 (USD BILLION)
FIGURE 21. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 22. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL & MAIL ORDER PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 23. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL & MAIL ORDER PHARMACIES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 24. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 25. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 26. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 27. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 28. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 29. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 30. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 31. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 32. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 33. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES CANCER BIOLOGICAL THERAPY MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 5. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 10. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL & MAIL ORDER PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 13. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 14. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 15. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 16. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 17. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 18. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 19. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 20. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 21. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 22. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 23. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 24. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 25. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 26. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 27. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 28. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 29. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 30. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 31. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 32. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 33. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 34. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 35. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 36. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET RANKING
TABLE 37. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2021
TABLE 38. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET MERGER & ACQUISITION
TABLE 39. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 40. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 41. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET INVESTMENT & FUNDING
TABLE 42. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 43. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie, Inc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EnGeneIC Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corp
  • Johnson & Johnson Services, Inc,
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer, Inc
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

Methodology

Loading
LOADING...